Cizzle Bio Study Supports CIZ1B for Early Lung Cancer
Dallas, Texas, September 1, 2026 Cizzle Bio, Inc. has announced the publication of a new peer-reviewed study providing additional...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dallas, Texas, September 1, 2026 Cizzle Bio, Inc. has announced the publication of a new peer-reviewed study providing additional...
Caesarea, Israel, August 13, 2026 IceCure Medical Ltd., a developer of minimally invasive cryoablation technology for tumor treatment, has...
BOSTON, Massachusetts — December 16, 2025 — CTT Pharmaceutical Holdings, Inc. (CTT Pharma) announced that its scientific team has...
